Grace Therapeutics, Inc. Operating Lease, Expense
Grace Therapeutics, Inc. (GRCE) reported Operating Lease, Expense of $0 for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2024-08-09
- Grace Therapeutics, Inc. operating lease, expense for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. operating lease, expense for the quarter ending 2024-03-31 was $23.00K, a 83.21% decline year-over-year.
- Grace Therapeutics, Inc. operating lease, expense for the quarter ending 2023-12-31 was $23.00K, a 4.55% increase year-over-year.
- Grace Therapeutics, Inc. operating lease, expense for the quarter ending 2023-06-30 was $23.00K.
- Grace Therapeutics, Inc. operating lease, expense for fiscal 2024 was $93.00K, a 54.85% decline from fiscal 2023.
- Grace Therapeutics, Inc. operating lease, expense for fiscal 2023 was $206.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 10-Q · filed 2024-08-09 | $23.00K derived: sum of 2 quarters · filed 2024-08-09 | $46.00K derived: sum of 3 quarters · filed 2024-08-09 | |
| 2024-03-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | $46.00K derived: sum of 2 quarters · filed 2024-06-21 | $93.00K 10-K · filed 2024-06-21 | |
| 2023-12-31 | $23.00K 10-Q · filed 2024-02-12 | $70.00K 10-Q · filed 2024-02-12 | ||
| 2023-06-30 | $23.00K 10-Q · filed 2024-08-09 | $160.00K derived: sum of 2 quarters · filed 2024-08-09 | $182.00K derived: sum of 3 quarters · filed 2024-08-09 | |
| 2023-03-31 | $137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | $159.00K derived: sum of 2 quarters · filed 2024-06-21 | $206.00K 10-K · filed 2024-06-21 | |
| 2022-12-31 | $22.00K 10-Q · filed 2024-02-12 | $69.00K 10-Q · filed 2024-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |